Targeting active and inactive CDK2 differential binding inhibitors

被引：0
|
作者：
Kontopidis, G. [1 ]
McInnes, C. [2 ]
Pandalaneni, S. [3 ]
McNae, I. [4 ]
Gibson, D. [5 ]
Mezna, M. [6 ]
Thomas, M. [5 ]
Wood, G. [5 ]
Wang, S. [7 ]
Walkinshaw, M. [4 ]
Fischer, P. [7 ]
机构：
[1] Univ Thessaly, Volos, Greece
[2] S Carolina Coll Pharm, Orangeburg, SC USA
[3] Univ Abertay, Dundee, Scotland
[4] Univ Edinburgh, Edinburgh, Midlothian, Scotland
[5] Cyclacel Pharmaceut, Dundee, Scotland
[6] Beatson Inst Canc Res, Beatson, Scotland
[7] Univ Nottingham, Nottingham NG7 2RD, England
来源：
FEBS JOURNAL | 2008年 / 275卷
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：408 / 408
页数：1
相关论文
共 50 条
  • [1] Differential binding of inhibitors to active and inactive CDK2 provides insights for drug design
    Kontopidis, G
    McInnes, C
    Pandalaneni, SR
    McNae, L
    Gibson, D
    Mezna, M
    Thomas, M
    Wood, G
    Wang, SD
    Walkinshaw, MD
    Fischer, PM
    CHEMISTRY & BIOLOGY, 2006, 13 (02): : 201 - 211
  • [2] Type II Inhibitors Targeting CDK2
    Alexander, Leila T.
    Moebitz, Henrik
    Drueckes, Peter
    Savitsky, Pavel
    Fedorov, Oleg
    Elkins, Jonathan M.
    Deane, Charlotte M.
    Cowan-Jacob, Sandra W.
    Knapp, Stefan
    ACS CHEMICAL BIOLOGY, 2015, 10 (09) : 2116 - 2125
  • [3] Inhibitor binding to active and inactive CDK2: The crystal structure of CDK2-cyclin A/indirubin-5-sulphonate
    Davies, TG
    Tunnah, P
    Meijer, L
    Marko, D
    Eisenbrand, G
    Endicott, JA
    Noble, MEM
    STRUCTURE, 2001, 9 (05) : 389 - 397
  • [4] Allostery governs Cdk2 activation and differential recognition of CDK inhibitors
    Majumdar, Abir
    Burban, David J.
    Muretta, Joseph M.
    Thompson, Andrew R.
    Engel, Tiffany A.
    Rasmussen, Damien M.
    Subrahmanian, Manu V.
    Veglia, Gianluigi
    Thomas, David D.
    Levinson, Nicholas M.
    NATURE CHEMICAL BIOLOGY, 2021, 17 (04) : 456 - 464
  • [5] Allostery governs Cdk2 activation and differential recognition of CDK inhibitors
    Abir Majumdar
    David J. Burban
    Joseph M. Muretta
    Andrew R. Thompson
    Tiffany A. Engel
    Damien M. Rasmussen
    Manu V. Subrahmanian
    Gianluigi Veglia
    David D. Thomas
    Nicholas M. Levinson
    Nature Chemical Biology, 2021, 17 : 456 - 464
  • [6] Computational design and synthesis of non-peptidic inhibitors targeting the cyclin binding groove of CDK2/Cyclin A
    Premnath, Padmavathy N.
    Bolger, Joshua K.
    Liu, Shu
    Campbell, McInnes
    CANCER RESEARCH, 2011, 71
  • [7] Targeting Conformational Activation of CDK2 Kinase
    Pellerano, Morgan
    Tcherniuk, Sergey
    Perals, Corine
    Thi Nhu Ngoc Van
    Garcin, Elsa D.
    Mahuteau-Betzer, Florence
    Teulade-Fichou, Marie-Paule
    Morris, May C.
    BIOTECHNOLOGY JOURNAL, 2017, 12 (08)
  • [8] Inhibitors and PROTACs of CDK2: challenges and opportunities
    Zeng, Yangjie
    Ren, Xiaodong
    Jin, Pengyao
    Fan, Zhida
    Liu, Mengguang
    Zhang, Yali
    Li, Linzhao
    Zhuo, Ming
    Wang, Jubo
    Li, Zhiyu
    Wu, Min
    EXPERT OPINION ON DRUG DISCOVERY, 2024, 19 (09) : 1125 - 1148
  • [9] Synthesis of potent oxindole CDK2 inhibitors
    Dermatakis, A
    Luk, KC
    DePinto, W
    BIOORGANIC & MEDICINAL CHEMISTRY, 2003, 11 (08) : 1873 - 1881
  • [10] The search of CDK2 inhibitors as anticancer agents
    Dubinina, GG
    Platonov, MO
    Kovalskyy, DB
    Borisko, PO
    Golovach, SM
    Dubyna, VM
    Tolmachov, AO
    ANNALS OF ONCOLOGY, 2005, 16 : 32 - 32
12345